Skip to main content
Equibles
BSPK logo

BSPK · Bespoke Extracts, Inc. · Metrics

Track BSPK — free

Use BSPK with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BSPK.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.00 At close · Nov 9
Rebalance outlook locked
Going-concern doubt — flagged Nov 12, 2025

Substantial doubt about the company's ability to continue as a going concern.

“The Company had negative cash flows from operations of $123,562 for period ended September 30, 2025, and a working capital deficit of $1,675,749 and accumulated deficit of $26,947,831, as of September 30, 2025. This raises substantial doubt about the Company's ability to continue as a going concern for a period of one year from the date of these financial statements.”
View the 10-Q filed Nov 12, 2025
Market Cap
$6,752
Shares
11.25M
Volume · Nov 9 134 Avg daily vol (8 sessions) 1209

BSPK metrics

50 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.00
Market cap
$6,752

Price action

23 metrics
Price change (1W)
—
Price change (30D)
—
Price change (3M)
-33.3%
Price change (6M)
-99.7%
Price change (YTD)
-99.7%
Price change (1Y)
-99.5%
Trailing year
Price change (5Y)
—
52-week high
$0.28
52-week low
$0.00
Change from 52-week high
-99.8%
Change from 52-week low
+20.0%
Annualized volatility
443.8%
Annualized volatility (3M)
—
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
—
RSI (14D)
30.7
Price vs SMA 50
-99.6%
Price vs SMA 200
-99.6%
Avg volume (3M)
—
Relative volume
—
Average dollar volume
—

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
11.25M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
1.4×
reciprocal yield 72.0%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.0×
reciprocal yield 21,075.5%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
407.3%
P / FCF
—
P / operating cash flow
—
Earnings yield
-10,819.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
407.3%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
47.2%
Operating margin
-45.0%
Trailing 12 months
Net margin
-51.3%
Gross profit (TTM)
$671,695
Operating profit (TTM)
−$640,301
Net income (TTM)
−$730,564
Trailing 12 months
Diluted EPS (TTM)
$-0.06
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.13
Gross profit per diluted share (TTM)
$0.06
Operating profit per diluted share (TTM)
$-0.06
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-0.07
Operating cash flow per diluted share (TTM)
$-0.02
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.21

Growth

11 metrics
Revenue growth YoY
+68.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.42M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+5.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-247.2%
Debt / equity
—
Current ratio
0.1
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$1.97M
Latest balance sheet
Cash & equivalents
$16,743
Total assets
$295,573
Total debt
$2.00M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$259,702
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
$1.16M
Stock compensation (TTM)
$93,281
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1409197 Visit website Investor relations